Xconomy Boston

BioVex, Inc. Lands $40,000,000 Series F Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ea819afd-0fdf-4a8c-8cad-e73ca7d6bb6a&Preview=1
Date
3/30/2009
Company Name
BioVex, Inc.
Mailing Address
34 Commerce Way Woburn, MA 01801
Company Description
The Company is developing a new class of potent biologics for the treatment
of cancer and prevention of infectious disease.
Website
http://www.biovex.com
Transaction Type
Venture Equity
Transaction Amount
$40,000,000
Transaction Round
Series F
Proceeds Purposes
Following the unprecedented number of durable complete remissions generated with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a pivotal Phase III study.
M&A Terms
Venture Investor
Forbion Capital Partners (FKA ABN)
Venture Investor
Harris & Harris Group
Venture Investor
New Science Ventures
Venture Investor
Triathlon Medical Ventures
Venture Investor
Innoven Partners
Venture Investor
SEP – Scottish Equity Partners